Format

Send to

Choose Destination
See comment in PubMed Commons below
J Pediatr Gastroenterol Nutr. 2013 Apr;56(4):376-81. doi: 10.1097/MPG.0b013e31827e1ee2.

Effect of high β-palmitate content in infant formula on the intestinal microbiota of term infants.

Author information

1
Technion-Israel Institute of Technology, Bnai Zion Medical Center affiliated with Rappaport Faculty of Medicine, Technion, Haifa, Israel. simay@tx.technion.ac.il

Abstract

OBJECTIVES:

Palmitic acid (PA) constitutes 17% to 25% of the human milk fatty acids, and ~70% is esterified in the sn-2 position of triglycerides (β-palmitate). In the sn-2 position, PA is not hydrolyzed and thus is efficiently absorbed. The PA in palm oils, commonly used in infant formulas, is esterified in the sn-1 and sn-3 positions. In these positions, PA is hydrolyzed and forms poorly absorbed calcium complexes. The present study assessed whether high β-palmitate in infant formulas affects the intestinal flora.

METHODS:

Thirty-six term infants were enrolled: 14 breast-fed (BF group) and 22 formula-fed infants who were randomly assigned to receive formula containing high β-palmitate (HBP group, n=14), or low β-palmitate (LBP group, n=8), where 44% and 14% of the PA was β-palmitate, respectively. The total amount of PA in the formulas was 19% and 22% in the LBP and HBP groups, respectively. Neither formula contained pre- or probiotics. Stool samples were collected at enrollment and at 6 weeks for the quantification of bacteria.

RESULTS:

At 6 weeks, the HBP and BF groups had higher Lactobacillus and bifidobacteria counts than the LBP group (P<0.01). The Lactobacillus counts at 6 weeks were not significantly different between the HBP and BF groups. Lactobacillus counts were 1.2×10¹⁰, 1.2×10¹¹, and 5.6×10¹⁰ CFU/g for LBP, HBP, and BF groups, respectively. Bifidobacteria counts were 5.1×10⁹, 1.2×10¹¹, and 3.9×10¹⁰ CFU/g for LBP, HBP, and BF groups, respectively.

CONCLUSIONS:

HBP formula beneficially affected infant gut microbiota by increasing the Lactobacillus and bifidobacteria counts in fecal stools.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT01116115.

PMID:
23201699
DOI:
10.1097/MPG.0b013e31827e1ee2
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Support Center